Fluoride

Fluoride

SCHEMBL1062136

CCN(CC)CC.F.[F-].[F-].[F-].[H+].[H+].[H+]

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.31
HRH3 Q9Y5N1 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fluoride SCHEMBL3926229 1.00 ALDH1A1 (0.31) ALDH1A1HRH3
Fluoride SCHEMBL633913 1.00
Fluoride SCHEMBL28235374 0.95
Fluoride Ion SCHEMBL963997 0.95
Fluoride Ion SCHEMBL131861 0.95 ALDH1A1 (0.33) ALDH1A1HRH3
Fluoride SCHEMBL1263596 0.95
Fluoride SCHEMBL6229645 0.95
SCHEMBL1334882 0.91
Fluoride SCHEMBL13581787 0.91 ALDH1A1 (0.36) ALDH1A1HRH3
Fluoride SCHEMBL99441 0.91

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9605261-B2 RNA synthesis—phosphoramidites for synthetic RNA in the reverse direction, and application in convenient introduction of ligands, chromophores and modifications of synthetic RNA at the 3′-end CHEMGENES CORPORATION (US) 2017-03-28 US disclosed
EP-2326656-B1 RNA SYNTHESIS - PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3' - END CHEMGENES CORP (US) 2017-01-25 EP disclosed
US-9512162-B2 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites and oligonucleotides ASED, LLC (US) 2016-12-06 US disclosed
US-9493773-B2 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides ASED, LLC (US) 2016-11-15 US disclosed
US-9365607-B1 Synthesis of deuterated ribo nucleosides, N-protected phosphoramidites, and oligonucleotides ASED, LLC (US) 2016-06-14 US disclosed
US-20150252071-A1 Synthesis of Deuterated Ribo Nucleosides, N-Protected Phosphoramidites and Oligonucleotides ASED, LLC 2015-09-10 US disclosed
US-20150218557-A1 RNA SYNTHESIS-PHOSPHORAMIDITES FOR SYNTHETIC RNA IN THE REVERSE DIRECTION, AND APPLICATION IN CONVENIENT INTRODUCTION OF LIGANDS, CHROMOPHORES AND MODIFICATIONS OF SYNTHETIC RNA AT THE 3'-END CHEMGENES CORPORATION 2015-08-06 US disclosed
EP-2882768-A2 SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES Ased, LLC (US) 2015-06-17 EP disclosed
US-9045521-B2 Synthesis of deuterated ribo nucleosides N-protected phosphoramidites, and oligonucleotides ASED, LLC (US) 2015-06-02 US disclosed
US-20150119565-A1 SYNTHESIS OF DEUTERATED RIBO NUCLEOSIDES, N-PROTECTED PHOSPHORAMIDITES, AND OLIGONUCLEOTIDES ASED, LLC 2015-04-30 US disclosed
US-7276337-B2 Compositions and methods for visual ribonuclease detection assays INTEGRATED DNA TECHNOLOGIES, INC. (US) 2007-10-02 US disclosed
EP-1788875-A2 NOVEL POLYNUCLEOTIDE SYNTHESIS LABELING CHEMISTRY Dharmacon, Inc. (US) 2007-05-30 EP disclosed
WO-2006033730-A2 NOVEL POLYNUCLEOTIDE SYNTHESIS LABELING CHEMISTRY DHARMACON, INC. (US) 2006-03-30 WO disclosed
US-6773885-B1 INTERNUCLEOTIDE LINKAGES ARE FLANKED BY FLUORESCENT REPORTER GROUPS AND DARK QUENCHER INTEGRATED DNA TECHNOLOGIES, INC. 2004-08-10 US disclosed
US-20040137479-A1 Compositions and methods for visual ribonuclease detection assays INTEGRATED DNA TECHNOLOGIES, INC. 2004-07-15 US disclosed
US-5750735-A CHEMICAL INTERMEDIATES FOR ANTIBIOTICS AMERICAN CYANAMID COMPANY (US) 1998-05-12 US disclosed
US-5744465-A Method of inhibiting a β-lactamase enzyme by administering novel 2-thiosubstituted carbapenems AMERICAN CYANAMID COMPANY (US) 1998-04-28 US disclosed
US-5623081-A USING BENZYLOXYACETALDEHYDE DIMETHYL ETHER, HALOGENATED 1-PHENYLMETHOXY-4-PENTEN-2-OL; CYCLIZATION LIN YANG-I (US) 1997-04-22 US disclosed
US-5602118-A A 2-((2-SUBSTITUTED ALKYL)FUR-3-YL)-THIO-),3-CARBOXY-2-CARBOPENEM DERIVATIVES; EFFECTIVE AGAINST BETA-LACTAM ANTIBIOTIC-RESISTANT BACTERIA AMERICAN CYANAMID COMPANY (US) 1997-02-11 US disclosed
EP-0617036-A2 Novel 2-thiosubstituted carbapenems AMERICAN CYANAMID COMPANY (US) 1994-09-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150252071-A1 Synthesis of Deuterated Ribo Nucleosides, N-Protected Phosphoramidites and Oligonucleotides NSUN3, DUT, RNGTT ALDH1A1 4252/4885HRH3 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.